Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 12708582)

1.

Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study.

Martin A, Koenig K, Anderson GM, Scahill L.

J Autism Dev Disord. 2003 Feb;33(1):77-85.

PMID:
12708582
2.

Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.

Reinblatt SP, DosReis S, Walkup JT, Riddle MA.

J Child Adolesc Psychopharmacol. 2009 Apr;19(2):119-26. doi: 10.1089/cap.2008.040.

3.
4.

Retrial of selective serotonin reuptake inhibitors in children with pervasive developmental disorders: a retrospective chart review.

Henry CA, Shervin D, Neumeyer A, Steingard R, Spybrook J, Choueiri R, Bauman M.

J Child Adolesc Psychopharmacol. 2009 Apr;19(2):111-7. doi: 10.1089/cap.2008.037.

PMID:
19364289
6.

Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.

Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ.

J Child Adolesc Psychopharmacol. 2006 Oct;16(5):599-610.

PMID:
17069548
7.

Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review.

Henry CA, Steingard R, Venter J, Guptill J, Halpern EF, Bauman M.

J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):187-95.

PMID:
16553539
8.

Use of citalopram in pervasive developmental disorders.

Namerow L, Thomas P, Bostic JQ, Prince J, Monuteaux MC.

J Dev Behav Pediatr. 2003 Apr;24(2):104-8.

PMID:
12692455
9.

Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability.

Kolevzon A, Mathewson KA, Hollander E.

J Clin Psychiatry. 2006 Mar;67(3):407-14. Review.

PMID:
16649827
10.

The use of selective serotonin reuptake inhibitors in autism and related disorders.

Posey DJ, Erickson CA, Stigler KA, McDougle CJ.

J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):181-6. Review.

PMID:
16553538
11.

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.

Owley T, Salt J, Guter S, Grieve A, Walton L, Ayuyao N, Leventhal BL, Cook EH Jr.

J Child Adolesc Psychopharmacol. 2006 Oct;16(5):517-24.

PMID:
17069541
12.

A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.

Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.

Health Technol Assess. 2008 May;12(14):iii-iv, ix-60.

13.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
14.

Fluvoxamine treatment of a child with severe PDD: a single case study.

Kauffmann C, Vance H, Pumariega AJ, Miller B.

Psychiatry. 2001 Fall;64(3):268-77.

PMID:
11708052
15.

T3 augmentation of SSRI resistant depression.

Abraham G, Milev R, Stuart Lawson J.

J Affect Disord. 2006 Apr;91(2-3):211-5. Epub 2006 Feb 17.

PMID:
16483669
16.

A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.

Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM.

J Clin Psychiatry. 2003 Jun;64(6):640-7.

PMID:
12823077
17.

A retrospective study of memantine in children and adolescents with pervasive developmental disorders.

Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ.

Psychopharmacology (Berl). 2007 Mar;191(1):141-7. Epub 2006 Oct 3.

PMID:
17016714
18.

An open-label trial of escitalopram in pervasive developmental disorders.

Owley T, Walton L, Salt J, Guter SJ Jr, Winnega M, Leventhal BL, Cook EH Jr.

J Am Acad Child Adolesc Psychiatry. 2005 Apr;44(4):343-8.

PMID:
15782081
19.

Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.

Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ.

J Child Adolesc Psychopharmacol. 2004 Summer;14(2):233-41.

PMID:
15319020
20.

[Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder].

Fukuda T, Sugie H, Ito M, Sugie Y.

No To Hattatsu. 2001 Jul;33(4):314-8. Japanese.

PMID:
11494573
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk